Navigation Links
In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors
Date:12/16/2009

SALT LAKE CITY, Dec. 16 /PRNewswire-FirstCall/ -- TechniScan, Inc. (OTC Bulletin Board: TSNI) ("TechniScan" or the "Company"), a medical device company engaged in the development and commercialization of an automated breast ultrasound imaging system, announced today that Joe Pepper, PhD, has been appointed to the TechniScan Board of Directors.

Board Chairman Ken Hungerford commented, "Joe has extensive experience running small to large medical devices companies, including GE OEC Medical and U-Systems, both of whom compete in the area of breast imaging. The TechniScan Board is excited to have Joe Pepper on the team and he has already made significant contributions to helping us bring TechniScan's SVARA (TM) Warm Bath Ultrasound closer to realization in the marketplace."

"Joe Pepper's outstanding educational background and expertise in the field of ultrasound breast imaging make him a perfect addition to our Board of Directors," added TechniScan CEO David C. Robinson. "His energy and enthusiasm for what we are trying to do with breast cancer detection is highly motivating, yet he knows how to ask the tough questions. He wants to make sure we have the best possible product and are aligning everything we do with the needs of the customer."

Since 2007, Joseph W. Pepper has served as a consultant to medical device start-ups. From 2003 until 2007, Dr. Pepper served as CEO of U-Systems, Inc., a privately backed start-up that developed automated ultrasound for the early detection of breast cancer in women with dense breast tissue. Dr. Pepper served as CEO for OEC Medical Systems, a NYSE-traded, mobile fluoroscopic imaging equipment manufacturer and seller, from 1997 until the sale of the company to GE Healthcare in 1999. Prior to joining OEC, Dr. Pepper spent 15 years with The BOC Group, Plc., where he served as president of Ohmeda Medical Devices, the healthcare subsidiary of BOC responsible for international selling and distribution of medical devices, and as president of Ohmeda Medical Equipment, which was responsible for Ohmeda's monitoring and anesthesia equipment business.

Dr. Pepper has a BS/MS in Engineering Science from Florida State University, a PhD in Mechanical Engineering from Stanford University and an MBA from The Harvard Business School.

Dr. Pepper commented, "I am excited about this opportunity to add my knowledge and perspective to TechniScan, a company I have admired for quite some time. The images I have seen have impressive specificity and have the potential to change the ways that radiologists and oncologists detect cancer in the breast." Pepper continued, "The TechniScan Board has outstanding depth and diversity of perspective. I am honored to be a part of the group and I feel confident that, with our collective experience, we can take TechniScan and help make its imaging modality the premier method for post-mammographic lesion detection for women."

About TechniScan, Inc.

Based in Salt Lake City, Utah, TechniScan, Inc. is a medical device company engaged in the development and commercialization of a non-invasive imaging tool designed to provide physicians with automated ultrasound images of the human breast. The system, known as SVARA (TM), uses a process called Warm Bath Ultrasound (WBU(TM)) to provide physicians with automated, 3D, ultrasound images of the physical structures within the breast. TechniScan's WBU(TM) imaging device (SVARA (TM)) is limited by US law to investigational use unless, and until, cleared by the FDA.

For more information, please visit www.techniscanmedical.com.

Forward Looking Statements

Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified by the use of words such as "anticipate, "believe," "expect," "future," "may," "will," "would," "should," "plan," "projected," "potential," "intend," and similar expressions. Such forward-looking statements, involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of TechniScan, Inc. (the "Company") to be materially different from those expressed or implied by such forward-looking statements. The Company's future operating results are dependent upon many factors, including risk factors discussed in the Company's periodic filings with the Securities and Exchange Commission, which are available for review at www.sec.gov, including the Company's Current Report on Form 8-K filed on October 16th, 2009. The Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

SOURCE TechniScan, Inc.


'/>"/>
SOURCE TechniScan, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Womens Sexual Health Company Changes Name in Preparation for Market Entry
2. Face Masks Fly Off Shelves in Preparation for Flu Season
3. CoreSpine Technologies Expands Spinal Disc Site Preparation Efforts
4. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
5. Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand
6. Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
7. AMDL Diagnostics, Inc. Enters Into Exclusive Distribution Agreement With Grifols USA, LLC to Advance Commercialization of DR-70 Onko-Sure(TM) Cancer Test
8. Paratek Pharmaceuticals Signs Worldwide License and Commercialization Agreement for PTK 0796, Broad-Spectrum Oral and IV Antibiotic in Phase 3
9. Dendreon Reports PROVENGE Regulatory and Commercialization Progress and Future Pipeline Plans at Analyst Event
10. Ipsogen Expands its US Market Presence Through Licensing Agreement With ARUP Laboratories for the Commercialization of JAK2 Molecular Diagnostic Assays
11. Wayne County Partners With TechTown to Launch Global Stem Cell Innovation and Commercialization Lab
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... Feb. 22, 2017 Summary Provides ... partnering deals and agreements entered into by the worlds ... http://www.reportlinker.com/p03605668-summary/view-report.html Description The Global Non-Small Cell Lung ... understanding and access to partnering deals and agreements entered ... - Trends in partnering deals - Top deals ...
(Date:2/22/2017)... and PUNE, India , February 22, 2017 ... was valued at $3,453 million in 2015 and is projected to reach $5,334 million ... implants segment held nearly two-fifths of the total market in 2015. ... ... ...
(Date:2/22/2017)... Feb. 22, 2017   Protein Sciences Corporation , ... Flublok® Influenza Vaccine , announced today that they donated ... Vaccine Introduction (PIVI) and the Mongolian Ministry of Health ... the flu.  The doses of Flublok have been distributed ... for health care workers, pregnant women, and ...
Breaking Medicine Technology:
(Date:2/22/2017)... , ... February 22, 2017 , ... The Waismann ... the thousands of individuals who have recently fallen victim to America’s opioid epidemic. Now, ... Orange County, California, where they are free from the shame, stigma, and harmful ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... exam and eligibility requirements effective with the April 2017 testing period. NACCM, a ... , “The Care Manager Certified (CMC) exam is periodically re-calibrated to ensure that ...
(Date:2/22/2017)... ... February 22, 2017 , ... Giving ... fewer trips the emergency room, fewer hospital admissions, and better blood pressure and ... Care® (AJMC®) finds. The study can be found here . , The ...
(Date:2/22/2017)... ... February 22, 2017 , ... In a 2012 ... doses or not filling a prescription because they could not afford to pay ... getting medications were 30-60%*. At the same time, hospitals, pharmacies, manufacturers ...
(Date:2/22/2017)... ... February 22, 2017 , ... Doctors on Liens is continuing ... ophthalmologist, Dr. Steven H. Rauchman, practicing at North Valley Eye Medical Group in ... liability, premise liability and other personal injury cases. These injuries have a major ...
Breaking Medicine News(10 mins):